Previous New Releases from NCBI BookshelfMirvetuximab Soravtansine (Elahere): Indication: As monotherapy indicated for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens: Reimbursement Recommendation [Internet].Mirvetuximab Soravtansine (Elahere): Indication: As monotherapy indicated for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens: Reimbursement Recommendation [Internet].
